Compare Natera Inc. Common Stock (NTRA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs T Rowe Price Group Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while T Rowe Price Group Inc trades at $99.49 (market cap $21.63B). The key difference: Natera Inc. Common Stock is far larger — about 2.6× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays a 5.13% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and T Rowe Price Group Inc for 115 Days on average.
| NTRA | TROW | |
|---|---|---|
Market Cap | $57.03B | $21.63B |
Volume | 1,131,157 | 2,302,405 |
Sector | Health | Financials |
52-Week High | $425.64 | $121.68 |
52-Week Low | $179.42 | $86.19 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $56.18B | $18.82B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
T. Rowe Price (TROW) trades at $99.62, down 4.2% today, with a bearish technical signal despite strong fundamentals including a 29.26% net income margin and 20.1% ROE. The stock shows attractive valuation with a P/E of 10.18 and P/B of 1.97, while recent earnings beat expectations in Q1 and Q2 2026. Assets under management reached $1.90 trillion in August 2026 despite net outflows, and the company maintains a strong dividend history with 40 years of consecutive increases.
TROW presents a value opportunity with solid profitability and dividend stability, though technical weakness and mixed analyst sentiment (21% buy, 63% hold) suggest near-term caution. The consensus price target of $110.50 implies 11% upside potential, but investors face risks from market-sensitive revenue and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
